Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 19/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.60 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14960632 | 0.76 | PTGS1 (0.67) | PTGS1PTGS2 | |
| SCHEMBL17258767 | 0.75 | PTGS1 (0.55) | PTGS1PTGS2SLC22A12 | |
| SCHEMBL28448365 | 0.75 | SLC22A12 (0.76) | PTGS1PTGS2SLC22A12 | |
| SCHEMBL14627251 | 0.75 | PTGS1 (0.53) | PTGS1PTGS2SLC22A12 | |
| SCHEMBL5806458 | 0.74 | PTGS1 (0.55) | PTGS1PTGS2 | |
| SCHEMBL19788231 | 0.74 | PTGS1 (0.55) | PTGS1PTGS2 | |
| SCHEMBL6871548 | 0.74 | — | — | |
| SCHEMBL6012692 | 0.74 | PTGS1 (0.55) | PTGS1PTGS2SLC22A12 | |
| SCHEMBL21048790 | 0.74 | SLC22A12 (0.63) | PTGS1PTGS2SLC22A12 | |
| SCHEMBL12320185 | 0.73 | PTGS1 (0.68) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PTGS1 1200/4885PTGS2 1462/4885SLC22A12 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.